How To Make the Best Alzheimer’s Treatment Decision

How To Make the Best Alzheimer’s Treatment Decisions

Diagnosing and Treating Alzheimer’s Disease

This Special Report provides all the facts you need to make informed decisions if you have to confront Alzheimer’s disease—the most common cause of dementia.

Yet we all worry. And not without reason.

Today, one in ten people 65 and older has Alzheimer’s disease (AD)—more than 5 million of us—yet only half of these people have actually been diagnosed with the disease. The rest don’t even know they have it! And it’s estimated that by 2050 as many as 16 million of us will have Alzheimer’s.

We read these statistics and think, “When (not if) will it happen to me or someone in my family?”

* * * * * * * * * * * *

The GOOD NEWS is that for most people, Alzheimer’s progresses very slowly. Deterioration of thinking, memory, and judgment are gradual, often taking place over many years. So you have time to learn about Alzheimer’s, to make the best treatment choices, and to plan for the future.

To help you, we asked Peter V. Rabins, M.D., M.P.H., to share his wisdom and hands-on experience with Alzheimer’s patients in a new in-depth report, Diagnosing and Treating Alzheimer’s Disease. The founding director of the Division of Geriatric Psychiatry and Neuropsychiatry at the Johns Hopkins School of Medicine, where he is a Professor of Psychiatry, emeritus, Dr. Rabins is co-author of the bestselling guide, The 36-Hour Day.

In the 109 years since Dr. Alois Alzheimer first described the symptoms of the disease, much has happened in brain research—but not enough. We still don’t have an easy way to diagnose AD with complete accuracy, nor do we have a cure.

What do we know? In Diagnosing and Treating Alzheimer’s Disease, you’ll learn how AD is currently diagnosed … the existing drugs that are used to treat it … and various new therapies that may some day provide better treatment. You’ll learn answers to key questions, such as:

• What is the current thinking about the cause of Alzheimer’s disease?

• What is the amyloid hypothesis and why is it under attack?

• Are amyloid plaques and neurofibrillary tangles the cause of Alzheimer’s or a byproduct of some other cause?

• How does beta-secretase prevent the build up of beta-amyloid?

• What happens when cholinergic neurons in the brain die?

• What’s the difference between having a genetic predisposition to Alzheimer’s and carrying a genetic mutation for Alzheimer’s disease?

• What’s the role of APOE in the formation of amyloid plaques?

• Does depression increase a person’s risk of developing Alzheimer’s? What about head injury?

• Studies suggest that lower early life education increases the risk of AD. Why?

Where Does Normal Forgetfulness End and
Mild Cognitive Impairment Begin?

• You will learn about laboratory tests that can aid in the diagnosis of AD, including: ADmark Assays, testing for APOE type, and the “sniff test,” a promising diagnostic tool currently under study.

• Additionally, Dr. Rabins clearly explains the use of MRI, fMRI, SPECT, PET, and CT—high tech brain scanning and imaging techniques that can help in detecting early AD.

Aricept, Razadyne, Exelon, Namenda—Do They Work?

Diagnosing and Treating Alzheimer’s Disease gets to the heart of these questions: we explore in depth the arguments for and against these AD drugs . explain the benefits and common side effects of each drug and answer frequently asked questions on the minds of many Alzheimer’s families:

• How do you determine which patient should be using an Alzheimer’s drug?

• How long do cholinesterase medications actually help?

• What happens if the patient does not respond to the medication?

• If one drug doesn’t work, should the patient try another?

• If the cholinesterase inhibitors are considered safe and efficacious, why are so many Alzheimer’s patients untreated or else taken off the drugs after just a short time?

What’s in the pipeline? You’ll read about:

• Aducanumab: The human monoclonal antibody immunotherapy that has already shown positive signs in a small group of patients in a Phase I study. You’ll learn why the drug company is now bypassing Phase II studies, going directly to Phase III trials involving thousands, and an outlay of more than $2 billion in anticipation of good results.

• ACI-35: This novel therapeutic vaccine is the first in the world to stimulate the patient’s immune system to produce antibodies against the tau protein. Phase II studies are expected to begin later this year.

• Statin Therapy, Anti-Inflammatory Drugs, and Estrogen—All have been investigated to treat Alzheimer’s disease. Where do we stand?

For example, depression in Alzheimer’s patients is common. It doesn’t appear like you’d expect it to, but it tends to respond to treatment. Dr. Rabins offers in-depth guidance on this crucial topic.

• Is depression an early symptom of Alzheimer’s disease?

• Should you tell a patient that he or she has Alzheimer’s?

• How is depression diagnosed in the Alzheimer’s disease patient?

• When is the right time to introduce medications to treat depression?

• Could antidepressants aggravate Alzheimer’s disease?

• What effect do antidepressants have on the biology of Alzheimer’s disease?

Scientific American Consumer Health is a partnership between Remedy Health Media and Scientific American. In addition to the Special Health Reports, our expanded product line includes the Health After 50 newsletter, White Papers and Bulletins.

You can count on Scientific American Consumer Health to bring you medical information that is trustworthy, impeccably researched and current.

The information in Diagnosing and Treating Alzheimer’s Disease is so critical to your wellbeing that we are making it available to you as a digital PDF download for only $49.95.

Still not sure you’ll benefit from this Special Report? No problem.
Our No-Strings, Can’t Lose, Must-Be-Satisfied Guarantee